OvaScience (OVAS) Earning Somewhat Positive News Coverage, Analysis Shows

Media coverage about OvaScience (NASDAQ:OVAS) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OvaScience earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.4225628845885 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of brokerages recently commented on OVAS. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of OvaScience in a research report on Monday, November 6th.

Shares of OvaScience (NASDAQ OVAS) remained flat at $$1.40 during trading hours on Friday. 308,890 shares of the company were exchanged, compared to its average volume of 532,365. OvaScience has a 12 month low of $1.25 and a 12 month high of $3.25.

COPYRIGHT VIOLATION NOTICE: “OvaScience (OVAS) Earning Somewhat Positive News Coverage, Analysis Shows” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/10/ovascience-ovas-earning-somewhat-positive-news-coverage-analysis-shows.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply